PE20230388A1 - CRYSTALLINE RET INHIBITOR - Google Patents
CRYSTALLINE RET INHIBITORInfo
- Publication number
- PE20230388A1 PE20230388A1 PE2022002417A PE2022002417A PE20230388A1 PE 20230388 A1 PE20230388 A1 PE 20230388A1 PE 2022002417 A PE2022002417 A PE 2022002417A PE 2022002417 A PE2022002417 A PE 2022002417A PE 20230388 A1 PE20230388 A1 PE 20230388A1
- Authority
- PE
- Peru
- Prior art keywords
- crystalline
- ret inhibitor
- ppm
- peaks
- selpercatinib
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Semiconductor Lasers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Una forma cristalina de selpercatinib, que se caracteriza por al menos uno de: (a) un patron de difraccion de rayos X en polvo (XRPD) que comprende un pico a 21,1 y uno o mas picos a 17,1 , 17,7 y 19,8 0,2 2? medidos utilizando una longitud de onda de rayos X de 1,5418 ; o (b) un espectro de NMR de 13C en estado solido que comprende picos referidos a la resonancia de campo alto de adamantano (? = 29,5 ppm) a: 28,0, 48,0, 80,4, 106,8, 130,2 y 134,9ppm ( 0,2 ppm, respectivamente).A crystalline form of selpercatinib, characterized by at least one of: (a) an X-ray powder diffraction (XRPD) pattern comprising a peak at 21.1 and one or more peaks at 17.1, 17, 7 and 19.8 0.2 2? measured using an X-ray wavelength of 1.5418; or (b) a solid state 13C NMR spectrum comprising peaks referred to the high field resonance of adamantane (? = 29.5 ppm) at: 28.0, 48.0, 80.4, 106.8 , 130.2 and 134.9ppm (0.2 ppm, respectively).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011701P | 2020-04-17 | 2020-04-17 | |
| US202163151354P | 2021-02-19 | 2021-02-19 | |
| PCT/US2021/026611 WO2021211380A1 (en) | 2020-04-17 | 2021-04-09 | Crystalline ret inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230388A1 true PE20230388A1 (en) | 2023-03-06 |
Family
ID=75747118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002417A PE20230388A1 (en) | 2020-04-17 | 2021-04-09 | CRYSTALLINE RET INHIBITOR |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP4136090A1 (en) |
| JP (2) | JP7608474B2 (en) |
| KR (1) | KR20230002706A (en) |
| CN (1) | CN115916791A (en) |
| AU (1) | AU2021255488B2 (en) |
| BR (1) | BR112022020446A2 (en) |
| CA (1) | CA3174316A1 (en) |
| CL (1) | CL2022002849A1 (en) |
| CO (1) | CO2022014882A2 (en) |
| CR (1) | CR20220520A (en) |
| DO (1) | DOP2022000221A (en) |
| EC (1) | ECSP22080982A (en) |
| IL (1) | IL297212A (en) |
| MX (1) | MX2022012952A (en) |
| PE (1) | PE20230388A1 (en) |
| PH (1) | PH12022552748A1 (en) |
| TW (1) | TWI865765B (en) |
| WO (1) | WO2021211380A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022069357A1 (en) * | 2020-10-01 | 2022-04-07 | Sandoz Ag | Crystalline form of selpercatinib |
| JP2024544772A (en) | 2021-12-13 | 2024-12-04 | ロクソ オンコロジー， インコーポレイテッド | Method for preparing crystalline form A of the RET inhibitor selpercatinib |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI704148B (en) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| TWI791053B (en) * | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | Crystalline forms of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile and pharmaceutical composition thereof |
| TWI783057B (en) * | 2017-10-10 | 2022-11-11 | 美商絡速藥業公司 | Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
| TWI812649B (en) * | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | Formulations of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile |
| CN114380825B (en) | 2018-09-30 | 2024-02-13 | 北京志健金瑞生物医药科技有限公司 | Substituted pyrazole condensed ring derivative and preparation method and application thereof |
| CN111004257B (en) | 2019-12-24 | 2021-06-29 | 武汉九州钰民医药科技有限公司 | Method for preparing RET inhibitor Selpercatinib |
-
2021
- 2021-04-07 TW TW110112512A patent/TWI865765B/en active
- 2021-04-09 CN CN202180043101.5A patent/CN115916791A/en active Pending
- 2021-04-09 CA CA3174316A patent/CA3174316A1/en active Pending
- 2021-04-09 AU AU2021255488A patent/AU2021255488B2/en active Active
- 2021-04-09 BR BR112022020446A patent/BR112022020446A2/en unknown
- 2021-04-09 PH PH1/2022/552748A patent/PH12022552748A1/en unknown
- 2021-04-09 EP EP21722702.4A patent/EP4136090A1/en active Pending
- 2021-04-09 MX MX2022012952A patent/MX2022012952A/en unknown
- 2021-04-09 PE PE2022002417A patent/PE20230388A1/en unknown
- 2021-04-09 IL IL297212A patent/IL297212A/en unknown
- 2021-04-09 CR CR20220520A patent/CR20220520A/en unknown
- 2021-04-09 JP JP2022562612A patent/JP7608474B2/en active Active
- 2021-04-09 KR KR1020227039684A patent/KR20230002706A/en active Pending
- 2021-04-09 WO PCT/US2021/026611 patent/WO2021211380A1/en active Application Filing
-
2022
- 2022-10-14 CL CL2022002849A patent/CL2022002849A1/en unknown
- 2022-10-17 EC ECSENADI202280982A patent/ECSP22080982A/en unknown
- 2022-10-17 DO DO2022000221A patent/DOP2022000221A/en unknown
- 2022-10-19 CO CONC2022/0014882A patent/CO2022014882A2/en unknown
-
2024
- 2024-10-10 JP JP2024177871A patent/JP2025020140A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021211380A1 (en) | 2021-10-21 |
| CR20220520A (en) | 2022-11-15 |
| AU2021255488A1 (en) | 2022-11-10 |
| JP2023522012A (en) | 2023-05-26 |
| CL2022002849A1 (en) | 2023-06-16 |
| CN115916791A (en) | 2023-04-04 |
| BR112022020446A2 (en) | 2022-11-29 |
| CO2022014882A2 (en) | 2022-10-31 |
| TWI865765B (en) | 2024-12-11 |
| ECSP22080982A (en) | 2023-01-31 |
| AU2021255488B2 (en) | 2024-05-30 |
| EP4136090A1 (en) | 2023-02-22 |
| TW202202501A (en) | 2022-01-16 |
| IL297212A (en) | 2022-12-01 |
| MX2022012952A (en) | 2023-01-11 |
| DOP2022000221A (en) | 2023-01-15 |
| PH12022552748A1 (en) | 2024-03-25 |
| JP2025020140A (en) | 2025-02-12 |
| CA3174316A1 (en) | 2021-10-21 |
| KR20230002706A (en) | 2023-01-05 |
| JP7608474B2 (en) | 2025-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230388A1 (en) | CRYSTALLINE RET INHIBITOR | |
| CN109313404B (en) | Radiation source | |
| Tong et al. | Probing the spectral and temporal structures of high-order harmonic generation in intense laser pulses | |
| UY27617A1 (en) | 2 - (PIRIDIN -2 - ILAMINO) - PIRIDO (2,3-D) PIRIMIDIN -7 WAVES | |
| CL2021000361A1 (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| AR064099A1 (en) | CRYSTAL FORM OF HEMIHYDRATE 1- (BETA-D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE | |
| WO2008155894A1 (en) | Optical waveform shaping device | |
| Brown | Synchrotron Emission on the Largest Scales: Radio Detection of the Cosmic-Web | |
| Angelakis et al. | Monitoring the radio spectra of selected blazars in the Fermi-GST era. The Effelsberg 100 m telescope covering the cm band | |
| WO2014128010A8 (en) | Euv light source for generating a used output beam for a projection exposure apparatus | |
| Shu-Min et al. | Developments at SSRF in soft x-ray interference lithography | |
| PH12022550221A1 (en) | Process-scale synthesis of a plasma kallikrein inhibitor | |
| AR121800A1 (en) | CRYSTALLINE RET INHIBITOR | |
| Takano | Beam diagnostics with synchrotron radiation in light sources | |
| TW200630604A (en) | Method and apparatus for inspection of optical component | |
| AR114245A1 (en) | FORMS OF CO-CRYSTALS OF AN ANALOGUE OF NOVOBIOCIN AND PROLIN | |
| KR101357883B1 (en) | Multiple interference device using time resolution | |
| Lommen et al. | Correlation between X-ray light-curve shape and radio arrival time in the Vela pulsar | |
| AR072139A1 (en) | BASE GEMCITABIN CRYSTAL POLYMORPHES | |
| CN105242500B (en) | Photoetching system based on ultraviolet broad spectrum Talbot self-imaging | |
| Iinuma et al. | Observation of second harmonics in laser–electron scattering using low energy electron beam | |
| Xie et al. | The Doppler effect and spectral energy distribution of blazars | |
| RU2013127415A (en) | METHOD FOR MEASURING ELECTRON DENSITY IN PLASMA BY OPTICAL SPECTROSCOPY METHOD | |
| Sun et al. | The intra-day optical monitoring of BL Lacerate object 1ES 1218+ 304 at its highest X-ray flux level | |
| Schott | Recent electroweak results from ATLAS at PLHC 2011 |